CAMPBELL; James J.

Patent Applications and Registrations

Patent applications and USPTO patent grants for CAMPBELL; James J..The latest application filed is for "methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2".

Company Profile

9.9.14

CAMPBELL; James J. - San Jose CA
Campbell; James J. - Mountain View CA
Campbell; James J. - Milwaukee WI
Campbell, James J. - Weymouth MA
Campbell; James J. - Palo Alto CA
Campbell; James J. - Medford NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Methods Of Treating Generalized Pustular Psoriasis With An Antagonist Of Ccr6 Or Cxcr2 App 20220280481 - CAMPBELL; James J. ; et al.	2022-09-08
Methods Of Treating Solid Tumors With Ccr2 Antagonists App 20220241290 - CAMPBELL; James J. ; et al.	2022-08-04
Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor Grant 11,304,952 - Campbell , et al. April 19, 2	2022-04-19
Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2 Grant 11,207,294 - Campbell , et al. December 28, 2	2021-12-28
Methods Of Treating Solid Tumors With Ccr2 Antagonists App 20210346361 - CAMPBELL; James J. ; et al.	2021-11-11
Methods of treating solid tumors with CCR2 antagonists Grant 11,154,556 - Campbell , et al. October 26, 2	2021-10-26
Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C--C chemokine receptor type 9 (CCR9) and anti-.alpha.4.beta.7 integrin blocking antibodies Grant 11,020,394 - Zeng , et al. June 1, 2	2021-06-01
Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies App 20210154292 - SCHALL; Thomas ; et al.	2021-05-27
Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies Grant 10,792,360 - Schall , et al. October 6, 2	2020-10-06
Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor App 20200297708 - CAMPBELL; James J. ; et al.	2020-09-24
Cxcr7 Inhibitors For The Treatment Of Cancer App 20200188410 - GOTOH; Noriko ; et al.	2020-06-18
Combination Therapy Using A Chemokine Receptor 2 (ccr2) Antagonist And A Pd-1/pd-l1 Inhibitor App 20190275015 - CAMPBELL; James J. ; et al.	2019-09-12
Methods Of Treating Solid Tumors With Ccr2 Antagonists App 20190269664 - CAMPBELL; James J. ; et al.	2019-09-05
Methods Of Treating Generalized Pustular Psoriasis With An Antagonist Of Ccr6 Or Cxcr2 App 20190209527 - CAMPBELL; James J. ; et al.	2019-07-11
Methods Of Treating Solid Tumors With Ccr2 Antagonists App 20190209573 - CAMPBELL; James J. ; et al.	2019-07-11
Combination Therapy Using A Chemokine Receptor 2 (ccr2) Antagonist And A Pd-1/pd-l1 Inhibitor App 20190134049 - CAMPBELL; James J. ; et al.	2019-05-09
Precharging apparatus and power converter Grant 9,787,210 - Patel , et al. October 10, 2	2017-10-10
Precharging Apparatus And Power Converter App 20160204709 - Patel; Yogesh P. ; et al.	2016-07-14
Modulation of systemic memory T cell trafficking App 20050169918 - Butcher, Eugene C. ; et al.	2005-08-04
Modulation of systemic memory T cell trafficking Grant 6,881,406 - Butcher , et al. April 19, 2	2005-04-19
Modulation of systemic memory T cell trafficking App 20020019341 - Butcher, Eugene C. ; et al.	2002-02-14
Modulation of systemic memory T cell trafficking Grant 6,245,332 - Butcher , et al. June 12, 2	2001-06-12
Multimode feed for a monopulse radar Grant 4,246,583 - Profera , et al. January 20, 1	1981-01-20

Company Registrations

NCAGE Code	52UV8	CAMPBELL JAMES J
CAGE Code	52UV8	CAMPBELL, JAMES J

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.